The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform
Keith W Ward - One of the best experts on this subject based on the ideXlab platform.
-
Retinal and systemic pharmacokinetics of the anti-inflammatory drug Cloricromene following oral administration in the rat and rabbit.
Journal of Ocular Pharmacology and Therapeutics, 2007Co-Authors: Claudio Bucolo, Francesco Maugeri, Adriana Maltese, Keith W WardAbstract:Purpose: The aim of this study was to evaluate the retina and plasma distribution of Cloricromene, a coumarin derivative, and its active metabolite (MET) after an oral administration in rabbits and rats. Methods: A single dose of Cloricromene was orally administered to rabbits (10 or 100 mg/kg) and to rats (100 mg/kg). Retina and plasma samples were collected at 15, 30, 60, and 90 min following administration. Drug concentrations in the retina and plasma were measured by high-performance liquid chromatography. Results: As anticipated, only the active metabolite was found in all samples. The retina and plasma showed the same Tmax; peak levels of the drug were achieved at 15 min in rats and at 30 min in rabbits. In rabbits, MET exposure was approximately dose-proportional in both retina and plasma between the 10- and 100-mg/kg dose. Substantial retinal exposure was observed in both the rat and rabbit, at exposures approximately nine- to sixteenfold lower in the retina than in plasma. Conclusions: The result...
Claudio Bucolo - One of the best experts on this subject based on the ideXlab platform.
-
Retinal and systemic pharmacokinetics of the anti-inflammatory drug Cloricromene following oral administration in the rat and rabbit.
Journal of Ocular Pharmacology and Therapeutics, 2007Co-Authors: Claudio Bucolo, Francesco Maugeri, Adriana Maltese, Keith W WardAbstract:Purpose: The aim of this study was to evaluate the retina and plasma distribution of Cloricromene, a coumarin derivative, and its active metabolite (MET) after an oral administration in rabbits and rats. Methods: A single dose of Cloricromene was orally administered to rabbits (10 or 100 mg/kg) and to rats (100 mg/kg). Retina and plasma samples were collected at 15, 30, 60, and 90 min following administration. Drug concentrations in the retina and plasma were measured by high-performance liquid chromatography. Results: As anticipated, only the active metabolite was found in all samples. The retina and plasma showed the same Tmax; peak levels of the drug were achieved at 15 min in rats and at 30 min in rabbits. In rabbits, MET exposure was approximately dose-proportional in both retina and plasma between the 10- and 100-mg/kg dose. Substantial retinal exposure was observed in both the rat and rabbit, at exposures approximately nine- to sixteenfold lower in the retina than in plasma. Conclusions: The result...
Francesco Maugeri - One of the best experts on this subject based on the ideXlab platform.
-
Retinal and systemic pharmacokinetics of the anti-inflammatory drug Cloricromene following oral administration in the rat and rabbit.
Journal of Ocular Pharmacology and Therapeutics, 2007Co-Authors: Claudio Bucolo, Francesco Maugeri, Adriana Maltese, Keith W WardAbstract:Purpose: The aim of this study was to evaluate the retina and plasma distribution of Cloricromene, a coumarin derivative, and its active metabolite (MET) after an oral administration in rabbits and rats. Methods: A single dose of Cloricromene was orally administered to rabbits (10 or 100 mg/kg) and to rats (100 mg/kg). Retina and plasma samples were collected at 15, 30, 60, and 90 min following administration. Drug concentrations in the retina and plasma were measured by high-performance liquid chromatography. Results: As anticipated, only the active metabolite was found in all samples. The retina and plasma showed the same Tmax; peak levels of the drug were achieved at 15 min in rats and at 30 min in rabbits. In rabbits, MET exposure was approximately dose-proportional in both retina and plasma between the 10- and 100-mg/kg dose. Substantial retinal exposure was observed in both the rat and rabbit, at exposures approximately nine- to sixteenfold lower in the retina than in plasma. Conclusions: The result...
Adriana Maltese - One of the best experts on this subject based on the ideXlab platform.
-
Retinal and systemic pharmacokinetics of the anti-inflammatory drug Cloricromene following oral administration in the rat and rabbit.
Journal of Ocular Pharmacology and Therapeutics, 2007Co-Authors: Claudio Bucolo, Francesco Maugeri, Adriana Maltese, Keith W WardAbstract:Purpose: The aim of this study was to evaluate the retina and plasma distribution of Cloricromene, a coumarin derivative, and its active metabolite (MET) after an oral administration in rabbits and rats. Methods: A single dose of Cloricromene was orally administered to rabbits (10 or 100 mg/kg) and to rats (100 mg/kg). Retina and plasma samples were collected at 15, 30, 60, and 90 min following administration. Drug concentrations in the retina and plasma were measured by high-performance liquid chromatography. Results: As anticipated, only the active metabolite was found in all samples. The retina and plasma showed the same Tmax; peak levels of the drug were achieved at 15 min in rats and at 30 min in rabbits. In rabbits, MET exposure was approximately dose-proportional in both retina and plasma between the 10- and 100-mg/kg dose. Substantial retinal exposure was observed in both the rat and rabbit, at exposures approximately nine- to sixteenfold lower in the retina than in plasma. Conclusions: The result...
P. B. Carrieri - One of the best experts on this subject based on the ideXlab platform.
-
No effect of Cloricromen on some coagulation parameters in patients with ischaemic cerebrovascular disease.
Journal of International Medical Research, 1994Co-Authors: G. Orefice, A. Grasso, Nicola Fazio, G. Del Vecchio, G. Volpe, M. Coppola, A. D'alessio, P. B. CarrieriAbstract:Cloricromen is a new drug that inhibits platelet aggregation in man and in experimental thrombosis. Twenty patients with a history of atherothrombotic stroke received Cloricromen (100 mg, twice daily) for 30 days in order to evaluate its effects on plasma fibrinogen, antithrombin III, and other variables of the haemostatic system. A statistically significant decrease in the prothrombin time (P < 0.01) was found only after 30 days of therapy. This decrease was transient and disappeared 15 days after the end of treatment. No statistically significant changes in plasma fibrinogen levels, antithrombin III, partial thromboplastin time, or platelet count were observed compared with baseline values. No side-effects were reported. This study did not reveal an effect of Cloricromen on coagulative variables in patients with cerebrovascular occlusive disease.